Pfizer Stock Forecast
NYSE: PFEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 2:19 PM ET
PFE analyst consensus
Consensus (28 analysts)
buy
Avg. price target
$28.91+4.03%
- Strong buy 2
- Buy 8
- Hold 16
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 28 Wall Street analysts covering Pfizer (2026-10-08), 10 rate the stock a buy or strong buy, 16 rate it a hold and 2 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $28.91, with a high estimate of $35.75 and a low estimate of $25.00. The average target implies upside of 4.0% from the current price of $27.79.
The spread between the highest and lowest targets is 43.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for PFE.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 7% |
| Buy | 8 | 29% |
| Hold | 16 | 57% |
| Sell | 1 | 4% |
| Strong sell | 1 | 4% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $25.00 | -10.04% |
| Average target | $28.91 | +4.03% |
| High target | $35.75 | +28.65% |